First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
… HC Chung reports grants to his institution and writing support from MSD during the conduct
of the study. He also reports grants to his institution from Amgen, BeiGene, BMS/Ono, GSK, …
of the study. He also reports grants to his institution from Amgen, BeiGene, BMS/Ono, GSK, …
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer …
YJ Bang, E Van Cutsem, A Feyereislova, HC Chung… - The Lancet, 2010 - thelancet.com
Background Trastuzumab, a monoclonal antibody against human epidermal growth factor
receptor 2 (HER2; also known as ERBB2), was investigated in combination with …
receptor 2 (HER2; also known as ERBB2), was investigated in combination with …
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label …
…, L Fornaro, T Olesiński, C Caglevic, HC Chung… - The Lancet, 2018 - thelancet.com
Background Patients with advanced gastric or gastro-oesophageal junction cancer that
progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel …
progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel …
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the …
…, R Shapira-Frommer, K Nakagawa, HC Chung… - The Lancet …, 2020 - thelancet.com
Background Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of high …
response to immune checkpoint blockade. We prospectively explored the association of high …
[HTML][HTML] Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE …
…, SA Piha-Paul, T Doi, B Gao, HC Chung… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Genomes of tumors that are deficient in DNA mismatch repair (dMMR) have high
microsatellite instability (MSI-H) and harbor hundreds to thousands of somatic mutations …
microsatellite instability (MSI-H) and harbor hundreds to thousands of somatic mutations …
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO …
…, N Boku, T Satoh, MH Ryu, Y Chao, K Kato, HC Chung… - The Lancet, 2017 - thelancet.com
Background Patients with advanced gastric or gastro-oesophageal junction cancer refractory
to, or intolerant of, two or more previous regimens of chemotherapy have a poor prognosis, …
to, or intolerant of, two or more previous regimens of chemotherapy have a poor prognosis, …
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
Background D2 gastrectomy is recommended in US and European guidelines, and is
preferred in east Asia, for patients with resectable gastric cancer. Adjuvant chemotherapy …
preferred in east Asia, for patients with resectable gastric cancer. Adjuvant chemotherapy …
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
…, J Tabernero, L Li, S Shah, P Bhagia, HC Chung - Nature, 2021 - nature.com
Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) amplification or
overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal …
overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal …
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma
DVT Catenacci, M Rosales, HC Chung, HH Yoon… - Future …, 2021 - Future Medicine
… HC Chung reports grants and research support from Amgen, BeiGene, Bristol-Myers
Squibb/Ono Pharmaceutical, Celltrion Healthcare, Lilly, GlaxoSmithKline, Incyte, Merck Serono, …
Squibb/Ono Pharmaceutical, Celltrion Healthcare, Lilly, GlaxoSmithKline, Incyte, Merck Serono, …
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro …
…, LT Chen, MH Ryu, DY Oh, SC Oh, HC Chung… - The Lancet …, 2022 - thelancet.com
Background The additive or synergistic sustained antitumour effect of immune checkpoint
inhibitors in combination with oxaliplatin-based chemotherapy has previously been reported. …
inhibitors in combination with oxaliplatin-based chemotherapy has previously been reported. …